A novel steroid and xenobiotic receptor (SXR) may be involved in chemoresistance, and we studied this receptor in endometrial cancer cell lines. The cisplatin (CDDP)-sensitive Ishikawa cell line and its CDDP-resistant sub-clone (ISIW+) were used. ISIW+ cells showed a much higher SXR expression. When Ishikawa cells were cultured with SXR anti-sense oligonucleotides (AS), the cells failed to pass crisis and did not gain cisplatin resistance. In an experiment using SCID mice, all AS-treated animals survived, whereas controls had 50% survival at 35 days. The present data indicate that SXR is a key system to induce, maintain and reverse a cisplatin-resistant phenotype in endometrial cancer cells.
Introduction
Cisplatin (cis-diamminedichloroplatinum(II) [CDDP])-based multidrug chemotherapy is the first choice of treatment for advanced ovarian, endometrial and cervical cancers in either adjuvant or neo-adjuvant settings. 1 This treatment has been shown to increase the cancer progression-free intervals but does not prolong survival: eventually, patients with advanced stage disease develop chemoresistance. 2, 3 Preventing cancer recurrence by suppressing the development of chemoresistance is a key objective in successfully controlling the disease. Several factors contribute to the development of chemoresistance. 4, 5 Aneuploidy and the expression of multidrug resistant (MDR), glutathione-S-transferase (GST)pi, and excisional repair genes have been shown to confer chemoresistant phenotypes. In a previous study we mapped gene expression in a CDDP-sensitive cell line as well as in a resistant sub-clone using gene array analysis, 6 and showed clear differences in GSTpi expression in resistant cells by means of an unknown mechanism. A potential induction pathway of GSTpi expression may involve the steroid and xenobiotic receptor (SXR), which has been implicated in the control of GST family expression. 7 The impact of the SXR and GSTpi on chemoresistant phenotypes in endometrial cancers is not understood, thus we explored the control mechanisms of SXR-GSTpi expression in endometrial cancer cell lines.
Materials and methods

CELL LINES AND ANIMALS
The Ishikawa human endometrial cancer cell line 8 and its CDDP-resistant sub-clone (ISIW+) were used in the in vitro studies. The establishment and characteristics of the ISIW+ cell line and the culture conditions were reported previously. 6 Briefly, cells were cultured in Eagle MEM medium (Nissui, Tokyo) supplemented with 10% fetal bovine serum (GIBCO, NY, USA). We used a medium without phenyl red, and the oestrogen level in the final incubation medium was adjusted to < 10 nM using a specific radioimmunoassay. ISIW+ cells (10 5 cells, Falcon 35 mm, 3002, Falcon, MA, USA) were then incubated with 1.86 µM CDDP (Billeting, Bristol Pharmaceuticals, K.K., Tokyo), and Ishikawa cells were incubated with the standard vehicle. Both cell lines were transplanted every 7 days. The numbers of viable cells in culture plates were counted using the WST-1 assay (Pre-mixed WST-1 cell proliferation assay system™, TAKARA, Tokyo) using a microplate recorder (MPR A4i™, TOSO, Tokyo).
Six-week-old CB-17/lcr SCID Jcl mice were used for the in vivo study. Animals were kept in a clean room with 12-h light and dark cycles. Water and pellets were given ad libitum. Animals (n = 10 per group) were injected intra-abdominally with Ishikawa or ISIW+ cells (10 6 cells), pre-treated with CDDP (7.46 µM) and either AS or NS (38 µg/ml), and their survival was monitored. Animals were sacrificed on day 14, and implants found in the abdominal cavity were counted.
In a separate set of experiments, 20 animals (10 per group) received the treatments described above, and animals were observed for 50 days.
EFFECTS OF SXR LIGAND ON CDDP RESISTANCE
The SXR is known to bind dexamethasone (DEX) and activates the expression of CYP3A4 or GSTA2, which are important enzymes in multiple-drug metabolisms. To study the direct effects of DEX binding and activation of the SXR on CDDP resistance, Ishikawa and ISIW+ cells (3000) were cultured in microplates (Corning, NY, USA, 25820) with 10 nM -10 µM of DEX for 48 h. The cells were then exposed to 10 µM CDDP for 48 h to determine if the cellular sensitivity to CDDP was altered.
GENE EXPRESSION STUDY
The SXR and GSTpi expression in cells was measured by reverse transcriptasepolymerase chain reaction (RT-PCR). The cells were quickly homogenized with a polytron homogenizer in 1 ml of ice-cold Zol B solution (RNA Zol B Isolation Mixture, TelTest Inc., USA). The mixture was further incubated at room temperature for 5 min to dissolve the cells. Using chloroform and isopropanol, whole RNA from the lysate was extracted. The extracted RNA was precipitated with ethanol and then dissolved in 20 µl of water. The reverse transcription with approximately 5 µg of the RNA templates was performed using the Firststrand cDNA Synthesis Kit (Pharmacia Biotech, NJ, USA). Synthesized cDNA was dissolved in 20 µl of water containing 0.2% diethylpyrocarbonate and stored at -80°C until used. SXR and GSTpi expression were evaluated using RT-PCR and the human SXR and GSTpi sequences were obtained from recent reports. 9 β-actin was also amplified as a control for the cDNA preparation. Briefly, 1 µg/µl of cDNA template was added to the PCR mixture containing 200 nM of adenosine triphosphate, thymidine triphosphate, cytidine triphosphate and guanosine triphosphate, 1 µM of primers, 1.25 mM MgCl 2 , 1.25 mM KCl and 2 IU of recombinant Taq polymerase (TAKARA, Tokyo, Japan) in 20 µl Tris-HCl buffer (pH 8.2). The PCR products were separated by 2% agarose gel electrophoresis, stained with ethidium bromide, and the density of the corresponding bands was measured using image-processing software (NIH Image, USA, version 6.0). The primers used in this study and their amplification conditions are shown in Table 1 .
Gene expression was measured by constructing a dose-response curve using cDNA from Ishikawa cells. A series of diluted standard cDNA solutions (1:2, 1:4, 1:8 and 1:10) was prepared; 6 µg cDNA from Ishikawa cells was the non-diluted standard. These standards were electrophoresed with the RT-PCR samples. The intensity of the gene expression of the test samples was normalized over the intensity of the β-actin control, and compared subjectively with the intensity of the cDNA standards.
SXR ANTI-SENSE OLIGONUCLEOTIDE EXPERIMENTS
Steroid and xenobiotic receptor anti-sense oligonucleotides (AS) against the DNA binding domain were constructed, and the effects were studied both in vitro and in vivo. The AS and non-sense oligonucleotide (NS) sequences are shown in Table 2 . Ishikawa and ISIW+ cells were cultured with 38 µg/ml of AS and NS for 48 h. The cells were then incubated with 10 µM of CDDP for 48 h. After CDDP treatment, approximately 3000 cells/150 µl were placed in the wells of micro-test plates (96 wells, Falcon, NJ, USA), 10 µl of the WST-1 mixture was added to the wells, and cells were stained for 2 h at 37°C. The viable cell numbers were estimated by reading the optical density (OD) at 450 nm, using an enzyme-linked immunosorbent assay (ELISA) plate reader.
STATISTICAL ANALYSIS
The SCID mouse survival was tested by Kaplan-Meier analysis, run with an SPSS package (SPSS, Tokyo). The difference in the gene expression was tested with the unpaired Student's t-test.
Results
The SXR expression was initially studied in Ishikawa and ISIW+ cells. The standard 61 N Takami, H Sakamoto, T Yamamoto SXR, cisplatin resistance and endometrial cancer N Takami, H Sakamoto, T Yamamoto SXR, cisplatin resistance and endometrial cancer curve generated from the serial dilution showed linearity ( Fig. 1 ) with amplification of < 30 cycles. SXR was expressed in both Ishikawa and ISIW+ cells. SXR expression measured by RT-PCR was estimated at 2.00 ± 0.25 and 8.00 ± 0.27 (mean ± SE) in Ishikawa and ISIW+ cells, respectively. SXR expression in ISIW+ cells was significantly higher than in Ishikawa cells (Student's t-test, P < 0.004; Fig. 2 ), suggesting that SXR interaction with a ligand may induce CDDP resistance. We tested the two cell lines for CDDP resistance after exposure to concentrations of 10 nM -10 µM DEX for 48 h. Fig. 3 shows that both Ishikawa and ISIW+ cell lines showed no apparent change in sensitivity to CDDP after treatment with DEX at concentrations of 10 nM -10 µM.
In vitro treatment with the AS inhibited SXR expression in both the Ishikawa and ISIW+ cells. Inhibition in Ishikawa cells was estimated to be 2.00 ± 0.25 versus 1.10 ± 0.21, whereas inhibition in ISIW+ cells was estimated to be 8.00 ± 0.27 versus 2.47 ± 0.20 (measurement in quadruplicates, three experiments repeated, mean ± SE, P < 0.001 for Ishikawa cells, and P < 0.0001 for ISIW+ cells; Fig. 4 ). GSTpi expression was N Takami, H Sakamoto, T Yamamoto SXR, cisplatin resistance and endometrial cancer also measured after AS treatment. AS inhibited GSTpi expression in Ishikawa cells (0.71 ± 0.68 versus 0.003 ± 0.006, P < 0.0001) but not in ISIW+ cells (2.63 ± 0.33 versus 2.56 ± 0.14, not significant; Fig. 5 ). When ISIW+ cells were cultured with AS or NS (38 µg/ml) before treatment with CDDP, the ISIW+ cells showed no resistance to CDDP (Fig. 6) . Also, when Ishikawa cells were chronically cultured with AS, cells failed to pass the crisis point and did not develop CDDP resistance (Fig. 7) .
The in vivo effects of AS were also evaluated using CB-17/lcr SCID Jcl mice. All 10 animals injected with ISIW+ cells pretreated with AS plus CDDP showed no visible intra-peritoneal implants. In contrast, six of 10 animals that received NS plus CDDP had intra-peritoneal implants (Fig. 8 ). In conclusion, AS treatment significantly inhibited implant formation (Fisher's exact test, P < 0.02).
In the 20 animals observed for 50 days, none died in the AS plus CDDP treatment group, whereas 50% of mice treated with NS plus CDDP died by day 37. All animals in the NS and CDDP treatment group died by day 50 post-injection, and the difference in survival between the two groups was highly significant (Log-rank test, P < 0.0001; Fig. 9 ).
Discussion
The novel orphan receptor, PXR, is activated by pregnanes and was originally cloned from a mouse liver cDNA library. 10 The human homologue, SXR, was then cloned from human liver cDNA. 11 SXR is activated by the pregnenolone derivatives, glucocorticoid and RU-38486. Activation results in transcription of CYP3A enzymes that are important in the detoxification/biotransformation of many drugs, 12 including anticancer agents such as CDDP. In addition, recent studies have shown that the SXR N Takami, H Sakamoto, T Yamamoto SXR, cisplatin resistance and endometrial cancer directly binds with a promoter sequence of the GSH gene 7 or P-glycoproteins. 13 In light of these findings, we tested the hypothesis that the SXR system plays an important role in the drug resistance of endometrial cancer.
Firstly, we established a CDDP-resistant sub-clone of the Ishikawa cell line, ISIW+. 6 Both Ishikawa and ISIW+ cell lines expressed SXR, indicating that these cells are able to operate the SXR-mediated system. To our knowledge, this is the first report of SXR in human endometrial cancer cells.
Interestingly, ISIW+ cellular expression of SXR was approximately four-fold higher than in the Ishikawa cell line, suggesting that SXR over-expression may be related to CDDP resistance. Based on this observation, we tested whether SXR-ligand binding promotes CDDP resistance. Although SXR has specificity for multiple drugs and xenobiotics such as RU 486, rifampicin, phenobarbital and paclitaxel, we selected N Takami, H Sakamoto, T Yamamoto SXR, cisplatin resistance and endometrial cancer DEX because DEX is frequently used in CDDP-taxol-based chemotherapy. CDDP sensitivity was unchanged within the range tested. We have concluded that the acute use of DEX, such as during chemotherapy, may not induce CDDP resistance, although it is not known if SXR-mediated CDDP resistance may develop over a period of weeks or months.
To determine the function of the SXR in both Ishikawa and ISIW+ cells, we constructed an AS against the DNA binding domain of the SXR. AS but not NS successfully inhibited SXR expression in vitro. In addition, when Ishikawa or ISIW+ cells were cultured with AS or NS, only AS reversed the CDDP resistance. Furthermore, SXR-AS blocked the mechanism by which Ishikawa cells transform into ISIW+ cells by chronic exposure to CDDP in vitro. Thus, in vitro data strongly suggest that SXR plays a key role in the development of CDDP resistance.
Studies have shown that CDDP induces
GSTpi and protects DNA from anti-cancer agents. 14, 15 GSTpi expression correlates with a clinical resistance to chemotherapy in ovarian cancers. 16 In endometrial cancer, however, the role of GSTpi is unknown. Barnette et al. 17 observed the presence of GSTpi in normal and cancerous endometrium. 17 GSTpi expression was lower in cancer patients who smoked, but no relationship between grade, outcome or chemoresistance was demonstrated. In the present study, we confirmed the expression of GSTpi in established endometrial cancer cells. In addition, we have shown that GSTpi expression is about four-fold higher in ISIW+ cells. Thus, GSTpi may play a role in CDDP resistance in the ISIW+ cell line. The SXR-AS, however, failed to inhibit GSTpi in ISIW+ cells. The altered response to the SXR-AS in ISIW+ cells may be due to promoter methylation as is seen in prostate adenocarcinoma. 18 Thus, SXR may cross-talk with GSTpi in cells sensitive to CDDP, such as Ishikawa cells. Alternatively, CDDP resistant cells, such as ISIW+ cells, may have a disrupted link. Nevertheless, SXR appears to be the primary point for development of CDDP resistance, since SXR-AS plus CDDP treatment in vivo prevented cancer implantation and demise in SCID mice.
Lastly, chronic exposure to CDDP induces resistance but the process was blocked by the SXR-AS. Since the SXR-AS itself does not inhibit growth, it either augments the CDDP effects or blocks the mechanism of acquisition of drug resistance. If SXR-AS can be administered along with CDDP-based chemotherapy, it may be possible to inhibit growth of CDDP-resistant cells. The mechanism requires further investigation but may provide a novel method of controlling drug resistance in endometrial cancer treatment. 
